OMass Therapeutics to Present New Preclinical Data For its Best-in-Class MC2 Program at ENDO 2025
OMass Therapeutics to Present New Preclinical Data For its Best-in-Class MC2 Program at ENDO 2025 GlobeNewswire July 07, 2025 Oxford, United Kingdom – 7th July 2025 – OMass Therapeutics ('OMass' or 'the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that preclinical data […]